3-(8,9-dihydroxynonyl)-1-methylthymine | 156918-35-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3-(8,9-dihydroxynonyl)-1-methylthymine
• 英文别名: 3-(8,9-dihydroxynonyl)-1,5-dimethylpyrimidine-2,4-dione
• CAS: 156918-35-3
• 化学式: C₁₅H₂₆N₂O₄
• 分子量: 298.382
• InChiKey: UFJZYAGAUDNSEL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  21
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  81.1
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(8,9-dihydroxynonyl)-1-methylthymine 、 溴化氢 在 碳酸氢钠 作用下， 以 (2S)-N-methyl-1-phenylpropan-2-amine hydrate 、 二氯甲烷 、 水 为溶剂， 以85%的产率得到3-(8-acetoxy-9-bromononyl)-1-methylthymine
  参考文献：
  名称：

  Halogen, isothiocyanate or azide substituted xanthines

  摘要：

  公开了一种具有以下公式的化合物：##STR1## 其中n是5到9的整数，核心基团是杂环基团，其中C.sub.a，C.sub.b和C.sub.c是R或S对映体或混合物，C.sub.a，C.sub.b和C.sub.c碳原子由单键，双键，乙醚或酯键连接，其中R.sub.1，R.sub.2和R.sub.3独立地是卤素，羟基，氢，酮，异硫氰酸酯，叠氮化物或卤代乙酸酯，但至少有一个R.sub.1，R.sub.2或R.sub.3必须是卤素，异硫氰酸酯，叠氮化物或卤代乙酸酯基团，其中R.sub.4为氢，C.sub.1-6烷基，C.sub.1-6烯基，环C.sub.4-6烷基或苯基，其中卤素指氟，氯，溴和碘及其盐和药物组成物。

  公开号：

  US05670506A1
• 作为产物：
  描述：

  3-(8-nonenyl)-1-methylthymine 、 N-甲基吗啉氧化物 、 、 Sodium Hydrosulfite, 85per cent 、 丙酮 在 二氯甲烷 、 水 、 solution 、 Sodium sulfate-III 、 乙醇 作用下， 以 水 为溶剂， 反应 18.25h， 以to yield 2.68 g (91% yield) 3-(8,9-dihydroxynonyl)-1-methylthymine (inventive compound no的产率得到3-(8,9-dihydroxynonyl)-1-methylthymine
  参考文献：
  名称：

  Epoxide-containing compounds

  摘要：

  本发明涉及公式I的对映体、二对映异构体、盐、溶剂物、水合物和其混合物，其中核心基团为具有五至六个环原子和1和3位置处的两个氮原子的单环环结构，n为4至16的整数，R.sub.1和R.sub.2为氢、卤素或C.sub.1-12烷基或烯基，而(CH.sub.2).sub.n可选择地被羟基、卤素、氧、C.sub.1-4烷基或二甲氨基基团取代。该化合物及其制药组合物在治疗通过第二信使介导的疾病或治疗引起的毒性的个体的方法中有用。

  公开号：

  US05866576A1

文献信息

• Therapeutic compounds containing pyrimidinyl moieties
  申请人：Cell Therapeutics, Inc.

  公开号：US05807862A1

  公开（公告）日：1998-09-15

  Therapeutic compounds with at least one carboxylic acid, ester or amide-substituted side chain have the formula: CORE MOIETY--(R).sub.j wherein j is an integer from one to three. The core moiety is non-cyclic or cyclic (carbocyclic or heterocyclic). R may be selected from among hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl, carbocyclic or heterocyclic groups and at least one R has the formula I: ##STR1## wherein: one or two p are the integer one, otherwise p is two; and n is an integer from three to twenty; R.sub.1 is selected from the group consisting of substituted and unsubstituted CH.sub.2 ; NR.sub.3, R.sub.3 being hydrogen, substituted or unsubstituted C.sub.(1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl or C.sub.(1-20) hydroxyalkyl, or carbocyclic or heterocyclic group; O; --CHR.sub.4 O--, R.sub.4 being substituted or unsubstituted C.sub.(1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl, C.sub.(1-20) hydroxyalkyl, or R.sub.2 and R.sub.4 join to form a substituted or unsubstituted heterocycle having four to seven ring atoms, the ether group --O-- of --CHR.sub.4 O-- being a member of the heterocycle. R.sub.2 is selected from the group consisting of hydrogen; halogen; substituted or unsubstituted C.sub.(1-10) alkyl; C.sub.(1-10) alkoxyl; C.sub.(2-10) alkenyl; C.sub.(1-10) hydroxyalkyl; --A(R.sub.5).sub.m, A being N or O, m being one or two and R.sub.5 being hydrogen, a substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(1-10) alkoxyl, C.sub.(2-10) alkenyl or C.sub.(1-10) hydroxyalkyl), or carbocyclic or heterocyclic group. At least one of R.sub.1 is NR.sub.3, O or --CHR.sub.4 O--, or R.sub.2 is --A(R.sub.5).sub.m. The compounds and pharmaceutical compositions thereof are useful as therapies for diseases advanced via intracellular signaling through specific intracellular signaling pathways by mediating a signaling response to an external stimuli.

  至少具有一个羧酸、酯或酰胺取代侧链的治疗化合物的公式为：CORE MOIETY--(R).sub.j，其中j是从1到3的整数。核心部分是非环状或环状（碳环或杂环）。R可以从氢、卤素、羟基、氨基、取代或未取代的C.sub.(1-10)烷基、C.sub.(2-10)烯基、碳环或杂环基团中选择，并且至少有一个R的公式为I：##STR1## 其中：一个或两个p是整数1，否则p是2；n是从3到20的整数；R.sub.1从所选的取代和未取代的CH.sub.2；NR.sub.3，其中R.sub.3为氢、取代或未取代的C.sub.(1-20)烷基、C.sub.(1-20)烷氧基、C.sub.(2-20)烯基或C.sub.(1-20)羟基烷基，或碳环或杂环基团中选择；O；--CHR.sub.4 O--，其中R.sub.4为取代或未取代的C.sub.(1-20)烷基、C.sub.(1-20)烷氧基、C.sub.(2-20)烯基、C.sub.(1-20)羟基烷基，或R.sub.2和R.sub.4连接形成具有四到七个环原子的取代或未取代的杂环，--CHR.sub.4 O--的醚基是杂环的成员。R.sub.2从氢、卤素、取代或未取代的C.sub.(1-10)烷基、C.sub.(1-10)烷氧基、C.sub.(2-10)烯基、C.sub.(1-10)羟基烷基、--A(R.sub.5).sub.m，其中A为N或O，m为1或2，R.sub.5为氢、取代或未取代的C.sub.(1-10)烷基、C.sub.(1-10)烷氧基、C.sub.(2-10)烯基或C.sub.(1-10)羟基烷基，或碳环或杂环基团中选择。至少有一个R.sub.1为NR.sub.3、O或--CHR.sub.4 O--，或者R.sub.2为--A(R.sub.5).sub.m。该化合物及其制药组合物可用作治疗通过介导对外部刺激的信号响应的特定细胞内信号通路而进展的疾病的疗法。
• Methods for using therapeutic compounds containing xanthinyl
  申请人：Cell Therapeutics, Inc.

  公开号：US06043250A1

  公开（公告）日：2000-03-28

  Therapeutic compounds with at least one carboxylic acid, ester or amide-substituted side chain have the formula: CORE MOIETY --(R).sub.j wherein j is an integer from one to three. The core moiety is non-cyclic or cyclic (carbocyclic or heterocyclic). R may be selected from among hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted C(.sub.1-10) alkyl, C(.sub.2-10) alkenyl, carbocyclic or heterocyclic groups and at least one R has the formula I: ##STR1## wherein: one or two p are the integer one, otherwise p is two; and n is an integer from three to twenty; R.sub.1 is selected from the group consisting of substituted and unsubstituted CH.sub.2 ; NR.sub.3, R.sub.3 being hydrogen, substituted or unsubstituted C(.sub.1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl or C.sub.(1-20) hydroxyalkyl, or carbocyclic or heterocyclic group; O; --CHR.sub.4 O--, R.sub.4 being substituted or unsubstituted C.sub.(1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl, C.sub.(1-20) hydroxyalkyl, or R.sub.2 and R.sub.4 join to form a substituted or unsubstituted heterocycle having four to seven ring atoms, the ether group --O-- of --CHR.sub.4 O-- being a member of the heterocycle. R.sub.2 is selected from the group consisting of hydrogen; halogen; substituted or unsubstituted C.sub.(1-10) alkyl; C.sub.(1-10) alkoxyl; C.sub.(2-10) alkenyl; C.sub.(1-10) hydroxyalkyl; --A(R.sub.5).sub.m, A being N or 0, m being one or two and R.sub.5 being hydrogen, a substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(1-10) alkoxyl, C.sub.(2-10) alkenyl or C.sub.(1-10) hydroxyalkyl), or carbocyclic or heterocyclic group. At least one of R.sub.1 is NR.sub.3, O or --CHR.sub.4 O--, or R.sub.2 is --A(R.sub.5).sub.m. The compounds and pharmaceutical compositions thereof are useful as therapies for diseases advanced via intracellular signaling through specific intracellular signaling pathways by mediating a signaling response to an external stimuli.

  至少具有一个羧酸、酯或酰胺取代的侧链的治疗化合物的公式为：CORE MOIETY --(R).sub.j，其中j是从1到3的整数。核心基团是非环状或环状（碳环或杂环）。R可以从氢、卤素、羟基、氨基、取代或未取代的C（.sub.1-10）烷基、C（.sub.2-10）烯基、碳环或杂环基团中选择，至少有一个R具有公式I：##STR1##其中：一个或两个p是整数1，否则p是2；n是从3到20的整数；R.sub.1从选自取代和未取代的CH.sub.2；NR.sub.3，R.sub.3为氢、取代或未取代的C（.sub.1-20）烷基、C.sub.（1-20）烷氧基、C.sub.（2-20）烯基或C.sub.（1-20）羟基烷基，或碳环或杂环基团；O；--CHR.sub.4 O--，R.sub.4为取代或未取代的C.sub.（1-20）烷基、C.sub.（1-20）烷氧基、C.sub.（2-20）烯基、C.sub.（1-20）羟基烷基，或R.sub.2和R.sub.4连接形成具有四至七个环原子的取代或未取代的杂环，--CHR.sub.4 O--的醚基--O--是杂环的成员。R.sub.2从选自氢、卤素、取代或未取代的C.sub.（1-10）烷基、C.sub.（1-10）烷氧基、C.sub.（2-10）烯基、C.sub.（1-10）羟基烷基；--A（R.sub.5）.sub.m，A为N或0，m为一或二，R.sub.5为氢、取代或未取代的C.sub.（1-10）烷基、C.sub.（1-10）烷氧基、C.sub.（2-10）烯基或C.sub.（1-10）羟基烷基，或碳环或杂环基团。至少有一个R.sub.1是NR.sub.3、O或--CHR.sub.4 O--，或R.sub.2是--A（R.sub.5）.sub.m。该化合物及其制药组合物可用作通过介导对外部刺激的信号响应来通过特定的细胞内信号通路推进的疾病的治疗方法。
• Therapeutic compounds containing xanthinyl
  申请人：Cell Therapeutics, Inc.

  公开号：US06100271A1

  公开（公告）日：2000-08-08

  Therapeutic compounds with at least one carboxylic acid, ester or amide-substituted side chain have the formula: CORE MOIETY --(R).sub.j wherein j is an integer from one to three. The core moiety is non-cyclic or cyclic (carbocyclic or heterocyclic). R may be selected from among hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl, carbocyclic or heterocyclic groups and at least one R has the formula I: ##STR1## wherein: one or two p are the integer one, otherwise p is two; and n is an integer from three to twenty; R.sub.1 is selected from the group consisting of substituted and unsubstituted CH.sub.2 ; NR.sub.3, R.sub.3 being hydrogen, substituted or unsubstituted C.sub.(1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl or C.sub.(1-20) hydroxyalkyl, or carbocyclic or heterocyclic group; O; --CHR.sub.4 O--, R.sub.4 being substituted or unsubstituted C.sub.(1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl, C.sub.(1-20) hydroxyalkyl, or R.sub.2 and R.sub.4 join to form a substituted or unsubstituted heterocycle having four to seven ring atoms, the ether group --O-- of --CHR.sub.4 O-- being a member of the heterocycle. R.sub.2 is selected from the group consisting of hydrogen; halogen; substituted or unsubstituted C.sub.(1-10) alkyl; C.sub.(1-10) alkoxyl; C.sub.(2-10) alkenyl; C.sub.(1-10) hydroxyallyl; --A(R.sub.5).sub.m, A being N or O, m being one or two and R.sub.5 being hydrogen, a substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(1-10) alkoxyl, C.sub.(2-10) alkenyl or C.sub.(1-10) hydroxyalkyl), or carbocyclic or heterocyclic group. At least one of R.sub.1 is NR.sub.3, O or --CHR.sub.4 O--, or R.sub.2 is --A(R.sub.5).sub.m. The compounds and pharmaceutical compositions thereof are useful as therapies for diseases advanced via intracellular signaling through specific intracellular signaling pathways by mediating a signaling response to an external stimuli.

  至少具有一个羧酸、酯或酰胺取代侧链的治疗化合物的化学式为：CORE MOIETY --(R).sub.j，其中j是从一到三的整数。核心基团是非环状或环状（碳环或杂环）。R可以从氢、卤素、羟基、氨基、取代或未取代的C.sub.(1-10)烷基、C.sub.(2-10)烯基、碳环或杂环基团中选择，至少一个R具有以下公式I： 其中：一个或两个p是整数一，否则p是二；n是从三到二十的整数；R.sub.1从以下组中选择：取代和未取代的CH.sub.2；NR.sub.3，R.sub.3为氢、取代或未取代的C.sub.(1-20)烷基、C.sub.(1-20)烷氧基、C.sub.(2-20)烯基或C.sub.(1-20)羟基烷基，或碳环或杂环基团；O；--CHR.sub.4 O--，R.sub.4为取代或未取代的C.sub.(1-20)烷基、C.sub.(1-20)烷氧基、C.sub.(2-20)烯基、C.sub.(1-20)羟基烷基，或R.sub.2和R.sub.4结合形成具有四到七个环原子的取代或未取代的杂环，--CHR.sub.4 O--的醚基--O--是杂环的成员。R.sub.2从以下组中选择：氢；卤素；取代或未取代的C.sub.(1-10)烷基；C.sub.(1-10)烷氧基；C.sub.(2-10)烯基；C.sub.(1-10)羟基烯基；--A(R.sub.5).sub.m，A为N或O，m为一或二，R.sub.5为氢、取代或未取代的C.sub.(1-10)烷基、C.sub.(1-10)烷氧基、C.sub.(2-10)烯基或C.sub.(1-10)羟基烷基，或碳环或杂环基团。至少有一个R.sub.1是NR.sub.3、O或--CHR.sub.4 O--，或R.sub.2是--A(R.sub.5).sub.m。该化合物及其制药组合物可用作通过介导对外部刺激的信号响应来通过特定的细胞内信号通路进行进展的疾病的治疗方法。
• NOVEL EPOXIDE-CONTAINING COMPOUNDS
  申请人：CELL THERAPEUTICS, INC.

  公开号：EP0662834A1

  公开（公告）日：1995-07-19
• EP0662834A4
  申请人：——

  公开号：EP0662834A4

  公开（公告）日：1996-04-17